Clinical trials: Carcinoma, Bronchogenic
Lung Cancer, Non Small Cell Lung Carcinoma
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
The trial investigates the feasibility and efficacy of targeting Non-Small Cell Lung Cancer (NSCLC) "driven" by epigenetic changes.
- Conditions
- Lung Cancer, Non Small Cell Lung Carcinoma, Hypermethylation
- Trial name
- NCT01209520
- Testing
- Cisplatin, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Miami
Non-small Cell Lung Cancer
Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer
Platinum-based combination chemotherapy, such as gemcitabine-carboplatin, is one of the standard first-line therapy for advanced non-small cell lung cancer (NSCLC).
- Trial name
- ISCAN (NCT01404260)
- Testing
- Gefitinib, Gemcitabine +Carboplatin
- Where
- China
- Volunteers
- 219 people
- Sponsor
- Guangdong Association of Clinical Trials
Carcinoma, Non-Small-Cell Lung
LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib
The objective of the Phase I step is to estimate the MTD at a dose level up to 50 mg/day (i.e., overseas recommended Phase II dose) in patients with advanced NSCLC and to determine the recommended dose for the Phase II step.
- Trial name
- NCT00711594
- Testing
- BIBW 2992 MA2 40mg/day, BIBW 2992 MA2 50mg/day, BIBW 2992 MA2 20mg/day
- Where
- 20 sites in Japan
- Volunteers
- 74 people
- Sponsor
- Boehringer Ingelheim
Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.
- Conditions
- Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma, Melanoma, Other Solid Tumors
- Trial name
- NCT02711345
- Testing
- LTT462
- Where
- 7 sites in United States, Germany and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
To better understand the safety and tolerability of ALKS 4230 in humans
- Trial name
- NCT02799095
- Testing
- ALKS 4230, ALKS 4230 + pembrolizumab
- Where
- 31 sites in United States, Australia and 5 more
- Volunteers
- 243 people
- Sponsor
- Mural Oncology, Inc
Carcinoma, Non-Small-Cell Lung
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC
This was a single-arm, open label, multicenter phase II, study of dabrafenib in combination with trametinib in Chinese participants with BRAF V600E mutation positive, stage IV NSCLC (American joint committee on cancer staging 8th…
- Trial name
- NCT04452877
- Testing
- Dabrafenib, Trametinib
- Where
- 8 sites in China
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine, carboplatin, and paclitaxel and work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00728845
- Testing
- bevacizumab, carboplatin, hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Carcinoma, Non-Small-Cell Lung
The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
The standard treatment for non-small cell lung cancer, stage IV or IIIB malignant pleural effusion is chemotherapy. The decision to use a regimen is currently determined by toxicity or by physician's preference.
- Trial name
- NCT00215930
- Testing
- Vinorelbine, Docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Carcinoma, Non-Small-Cell Lung
ADAM-Afatinib Diarrhea Assessment and Management
This is a non-randomized, open label, two-cohort, multi-institutional study to evaluate the use of diarrheal management tools intended to facilitate timely intervention and treatment modifications due to afatinib…
- Trial name
- NCT01814553
- Testing
- afatinib, loperamide
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one…
- Trial name
- NCT00769067
- Testing
- Erlotinib, PF-00299804
- Where
- 59 sites in United States, Australia and 10 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Small Cell Lung Cancer
DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
This study will test the safety of the study drug, DS-3201b, given in combination with irinotecan to people who have recurrent small cell lung cancer (SCLC).
- Trial name
- NCT03879798
- Testing
- DS-3201b, irinotecan
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer
Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS
This Phase II study consists of 2 parts: 1) pre-screening phase and 2) treatment phase. The pre-screening phase will investigate the presence of HRAS mutations in subjects with a histologically or cytologically confirmed…
- Trial name
- NCT03496766
- Testing
- Tipifarnib
- Where
- 30 sites in Spain
- Volunteers
- 9 people
- Sponsor
- Spanish Lung Cancer Group
Non-small Cell Lung Cancer
Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy
The purpose of this study is to determine if Pemetrexed plus Carboplatin plus Bevacizumab plus Enzastaurin, followed by maintenance Bevacizumab plus Enzastaurin can extend survival time without disease progression in the…
- Trial name
- NCT00533429
- Testing
- enzastaurin, pemetrexed, carboplatin
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors, Non-small Cell Lung Cancer
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
This is the first human study to use X-396 (ensartinib), a drug being developed for treatment of advanced cancers. The initial purpose of the study is to determine the largest amount of X-396 that can be safely given to humans…
- Trial name
- NCT01625234
- Testing
- Phase I: X-396 (ensartinib), Phase II: X-396 (ensartinib)
- Where
- 14 sites in United States
- Volunteers
- 131 people
- Sponsor
- Xcovery Holdings, Inc.
Non-Small Cell Lung Cancer Stage IV
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer
The main purpose of this study is to evaluate the effectiveness of the study drug known as abemaciclib versus docetaxel in participants with stage IV squamous non-small cell lung cancer (NSCLC) previously treated with…
- Trial name
- NCT02450539
- Testing
- Abemaciclib, Docetaxel
- Where
- 51 sites in United States, Australia and 11 more
- Volunteers
- 159 people
- Sponsor
- Eli Lilly and Company
Non Small Cell Lung Cancer
Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Patients affected by non-small cell lung cancer (NSCLC) will be treated in pemetrexed monochemotherapy regimen for a maximum of 8 cycles.
- Trial name
- NCT00370292
- Testing
- Pemetrexed - Before Protocol Amendment, Pemetrexed - After Protocol Amendment
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
- Trial name
- NCT02273375
- Testing
- MEDI4736
- Where
- 271 sites in United States, Australia and 17 more
- Volunteers
- 1,415 people
- Sponsor
- Canadian Cancer Trials Group
Non Small Cell Lung Cancer
First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin
The research study is testing the investigational drug necitumumab in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy…
- Trial name
- INSPIRE (NCT00982111)
- Testing
- Pemetrexed, Cisplatin, Necitumumab
- Where
- 101 sites in United States, Australia and 18 more
- Volunteers
- 633 people
- Sponsor
- Eli Lilly and Company
Melanoma, Meningioma
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT01967823
- Testing
- Anti-NY ESO-1 mTCR PBL, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer (NSCLC)
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study was to evaluate the efficacy and safety of tislelizumab in combination with sitravatinib compared to docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) who…
- Trial name
- NCT04921358
- Testing
- Tislelizumab, Docetaxel, Sitravatinib
- Where
- 61 sites in Australia, China
- Volunteers
- 377 people
- Sponsor
- BeiGene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.